What the Longevity Research Community Is Talking About

Longevity science moves fast, and the conversations happening in research labs, at conferences, and in the peer-reviewed literature right now will shape the supplement and therapeutic landscape over the next several years. This update covers the developments getting the most serious attention in the longevity research community in 2025 — the ideas with genuine scientific momentum, not just the ones generating the most consumer enthusiasm.

Partial Cellular Reprogramming: The Field’s Biggest Long-Term Bet

No area of longevity science has generated more research attention and investor capital over the past two years than partial cellular reprogramming — the approach of using transient expression of Yamanaka factors to reset the epigenetic state of aged cells without fully erasing their cellular identity. This is the research direction most directly connected to the sirtuin and epigenetic information theory of aging discussed throughout this site.

A significant 2025 paper from Juan Carlos Izpisúa Belmonte’s group, published in Cell, demonstrated that partial reprogramming could reverse what they termed “mesenchymal drift” — a common pattern in which aged cells across multiple organ types shift from orderly, functional epithelial states toward stiffer, scar-like mesenchymal states. This drift was found to occur in many organs and is associated with chronic diseases. In aged mice, partial reprogramming reversed this drift and restored more youthful gene expression patterns across multiple tissues simultaneously.

The distance between this mouse research and any clinical intervention is still substantial — gene therapy delivery of reprogramming factors to humans carries safety challenges that are actively being worked on but not yet resolved. The therapeutic timelines being discussed range from five to fifteen years for first human applications in specific contexts. What makes this area worth tracking for supplement users is that it is the research most directly testing whether biological aging is fundamentally reversible — and the answer coming from mouse studies is increasingly yes, in principle. The coverage of what epigenetic clock reversal means and what the evidence shows is in the article on can you actually reverse biological age?

SGLT2 Inhibitors as Senolytics: A Surprise Finding with Implications

One of the more striking findings of 2025 was the discovery that SGLT2 inhibitors — the class of diabetes drugs including empagliflozin and dapagliflozin, already known for their cardiovascular and renal protective effects — reduce senescence markers in humans. This finding suggests the benefits of SGLT2 inhibitors extend far beyond disease etiologies linked with glucose control to mechanistic targets of aging.

This is notable because it represents the first common pharmaceutical class with an established safety record and widespread clinical use that has been shown to have senolytic-like activity in humans. If confirmed in larger trials specifically designed to test this mechanism, it would mean that SGLT2 inhibitors — already prescribed to tens of millions of people for diabetes and heart failure — are also partially addressing one of the most important aging hallmarks as a side effect of their primary mechanism. The implications for how longevity researchers think about drug repurposing are significant.

For people already taking SGLT2 inhibitors for metabolic or cardiovascular indications, this is reassuring context. For the longevity supplement community, it raises interesting questions about how SGLT2 inhibitors compare to or interact with natural senolytic protocols using fisetin and quercetin. That comparison has not been directly studied.

The TAME Trial: Still Running, Still Relevant

The Targeting Aging with Metformin (TAME) trial — the large, multi-site randomized controlled trial designed to test whether metformin delays the onset of age-related diseases in non-diabetic older adults — remains ongoing and continues to be one of the most-discussed trials in geroscience. The trial will follow participants aged 65–80 for approximately six years, tracking the onset of major age-related diseases as a composite endpoint. Enrollment is proceeding, though the trial has faced funding challenges that have created uncertainty about its timeline.

The significance of TAME for the broader longevity field goes beyond whether metformin itself works. TAME was the first trial designed with FDA cooperation to test a compound against the aging process itself as an endpoint rather than a specific disease — if it succeeds, it establishes the clinical trial framework that other longevity interventions could use. That framework would potentially be more relevant for testing NMN, rapamycin, or senolytics against aging endpoints than any currently available trial design. The TAME results, whenever they arrive, will matter for the entire field.

Rapamycin for Healthy Aging: Moving Toward Human Evidence

Rapamycin — the mTOR inhibitor with the most robust longevity evidence of any single compound in mammalian models — is generating increasing human evidence at the lower, intermittent doses being explored in longevity contexts. Where continuous therapeutic doses of rapamycin carry significant immunosuppressive side effects, the intermittent lower-dose protocols used in longevity medicine (weekly or biweekly dosing at doses substantially below therapeutic levels) have not produced meaningful immunosuppression in the human pilot data published to date.

The longevity research community is increasingly viewing rapamycin as the compound with the most compelling animal evidence and the most promising early human safety signals — stronger than metformin on the animal data side, though with less human longevity outcome data given TAME’s ongoing status. Several clinical trials examining rapamycin in healthy older adults for various aging-related endpoints are underway or recently completed, with results expected to substantially clarify rapamycin’s role in accessible longevity medicine over the next two to three years.

AI-Accelerated Drug Discovery: Finding New Longevity Compounds Faster

Artificial intelligence is beginning to meaningfully accelerate the identification of new longevity compounds, and the longevity research community is paying close attention. A 2025 Scripps Research study demonstrated a 70% success rate in finding life-extending compounds in model organisms using AI-guided screening — substantially higher than the historical rate from conventional screening approaches. The NIA Interventions Testing Program, which systematically tests compounds for lifespan extension in mice, has seen its theoretical pipeline expand significantly as AI identifies new candidate compounds for testing.

The practical implication for the supplement space is a multi-year lag: compounds identified through AI screening in 2025 will need to complete mouse trials, then early human trials, before any consumer-accessible product could responsibly be made. But the acceleration of the identification stage is real and will produce new candidate longevity compounds at a faster rate than the field has historically managed.

The Shift Toward Healthspan and Functional Endpoints

A conceptual shift that has become more pronounced in 2025 is the longevity research community’s increasing emphasis on healthspan — years of healthy, functional life — as the primary outcome of interest rather than lifespan per se. This shift matters for how trials are designed and what counts as a successful outcome.

Rather than just looking at biomarker changes — NAD+ levels, epigenetic age scores, inflammatory markers — upcoming large trials are increasingly being designed around functional outcomes: physical performance, cognitive function, independence, and time free of major chronic disease. The TAME trial uses a disease-onset composite endpoint; newer trial designs are pushing toward direct functional measures. This trend is good news for the field’s credibility: functional outcomes are harder to measure than biomarkers but are the outcomes that actually matter to the people who would use longevity interventions.

For people following their own longevity protocols with NMN and the broader stacks covered on this site, the shift toward healthspan framing reinforces the tracking approach already recommended: functional measures like VO2 max, grip strength, and cognitive assessments alongside biological age scores give a more complete picture than biomarkers alone. The practical testing guide is in the article on how to test your NAD+ levels.

The Bottom Line for Supplement Users

The longevity research community in 2025 is broader, better-funded, and generating higher-quality human evidence than at any previous point in the field’s history. The most exciting developments — partial reprogramming, precision senolytics, AI-identified compounds — are years to decades away from clinical application. The most immediately relevant developments — SGLT2 inhibitors as senolytics, the TAME framework, rapamycin’s improving human evidence — are important context for understanding where the field is heading and how the supplement protocols available today relate to the therapeutic landscape that is coming.

The supplements covered throughout this site — NMN, NR, fisetin, quercetin, berberine, spermidine — are the accessible current-generation tools for supporting the same biological pathways that the longevity research community is most focused on. They will be joined and eventually partly superseded by more targeted interventions as the clinical evidence matures. In the meantime, they represent the best available evidence-based approach to supporting longevity biology without waiting for the next generation of therapies to complete their development pipelines.